| 1. |
2 Wierda W, O’Brien S, Wen S,
et al . Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol , 2005, 23(4): 4070-4078.
|
| 2. |
王建祥, 邱錄貴, 李建勇, 等. 中國慢性淋巴細胞白血病診斷與治療專家共識. 中國血液學雜志, 2010, 31(2): 141-144.
|
| 3. |
Alinari L, Lapalombella R, Andritsos L, et al . Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene , 2007, 26(23), 3644-3653.
|
| 4. |
Robak T, Dmoszynska A, Solal-Céligny P, et al . Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol , 2010, 28(10): 1756-1765.
|
| 5. |
http://www.cancer.gov/clinicaltrials/results/summary/2009/rituximab-cll0109/print.
|
| 6. |
Tsimberidou AM, Kantarjian HM, Cortes J, et al . Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer , 2003, 97(7): 1711-1720.
|
| 7. |
Anonymous. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia. Semin Oncol , 1993, 20(5 Suppl 7): 21-23.
|
| 8. |
Kharfan-Dabaja MA, Kumar A, Behera M, et al . Systematic review of high dose chemotherapy and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: what is the published evidence? Br J Haematol , 2007, 139(2): 234-242.
|
| 9. |
Hallek M, Cheson BD, Catovsky D, et al . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood , 2008, 111(23): 5446-5456.
|
| 10. |
Sorror ML, Storer BE, Maloney DG, et al . Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood , 2008, 111(1): 446-452.
|
| 11. |
Dreger P, Döhner H, Ritgen M, et al . Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood , 2010, 116(14): 2438-2447.
|
| 12. |
Rabinowe SN, Soiffer RJ, Gribben JG, et al . Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood , 1993, 82(4): 1366-1376.
|
| 13. |
Khouri IF, Keating MJ, Vriesendorp HM, et al . Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol , 1994, 12(4):748-758.
|
| 14. |
Gribben JG, Zahrieh D, Stephans K, et al . Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood , 2005, 106(13): 4389-4396.
|
